Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer

Cancer Genetics

Volumn 204, Issue 8, 2011, Pages 439-446

  Pinto, Pedro ^a   Rocha, Patrícia ^a   Veiga, Isabel ^a   Guedes, Joana ^a   Pinheiro, Manuela ^a   Peixoto, Ana ^a   Pinto, Carla ^a   Fragoso, Maria ^a   Sanches, Evaristo ^a   Araújo, António ^b   Alves, Fernando ^c   Coutinho, Camila ^d   Lopes, Paula ^a   Henrique, Rui ^a,e   Teixeira, Manuel R ^a,e  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b Centro Hospitalar de Entre Douro e Vouga   (Portugal)

^c Centro Hospitalar Trás Montes e Alto Douro   (Portugal)

^d Centro Hospitalar do Alto Ave ^*  (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

Author keywords

KRAS; Metastatic colorectal cancer; Mutation detection

Indexed keywords

ACCURACY; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CODON; COLORECTAL CANCER; CONTROLLED STUDY; EXON; GENE FREQUENCY; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; METASTASIS; MUTATION RATE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PREDICTION; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; TUMOR VOLUME; WILD TYPE; COLORECTAL TUMOR; COMPARATIVE STUDY; DNA SEQUENCE; GENETICS; METHODOLOGY; MUTATION; PROGNOSIS;

DNA; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

COLORECTAL NEOPLASMS; DNA, NEOPLASM; HUMANS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 84856399968     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2011.07.003     Document Type: Article

References (28)

1. Ferlay J., Autier P., Boniol M., et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592.
2. Worthley D.L., Whitehall V.L., Spring K.J., et al. Colorectal carcinogenesis: road maps to cancer. World J Gastroenterol 2007, 13:3784-3791.
3. Smith G., Carey F.A., Beattie J., et al. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A 2002, 99:9433-9438.
4. Calistri D., Rengucci C., Seymour I., et al. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Physiol 2005, 204:484-488.
5. Arends J.W. Molecular interactions in the Vogelstein model of colorectal carcinoma. J Pathol 2000, 190:412-416.
6. Takayama T., Miyanishi K., Hayashi T., et al. Colorectal cancer: genetics of development and metastasis. J Gastroenterol 2006, 41:185-192.
7. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
8. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007, 67:2643-2648.
9. De Roock W., Piessevaux H., De Schutter J., et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008, 19:508-515.
10. Di Fiore F., Blanchard F., Charbonnier F., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007, 96:1166-1169.
11. Khambata-Ford S., Garrett C.R., Meropol N.J., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007, 25:3230-3237.
12. Lievre A., Bachet J.B., Boige V., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26:374-379.
13. Bokemeyer C., Bondarenko I., Makhson A., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-671.
14. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664.
15. Allegra C.J., Jessup J.M., Somerfield M.R., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27:2091-2096.
16. Krypuy M., Newnham G.M., Thomas D.M., et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 2006, 6:295.
17. Ogasawara N., Bando H., Kawamoto Y., et al. Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers. Jpn J Clin Oncol 2011, 41:52-56.
18. Lurkin I., Stoehr R., Hurst C.D., et al. Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One 2010, 5:e8802.
19. Pearson H., Stirling D. DNA extraction from tissue. Methods Mol Biol 2003, 226:33-34.
20. Tomizawa Y., Iijima H., Sunaga N., et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 2005, 11:6816-6822.
21. Franklin W.A., Haney J., Sugita M., et al. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn 2010, 12:43-50.
22. Oliner K., Juan T., Suggs S., et al. A comparability study of 5 commercial KRAS tests. Diagn Pathol 2010, 5:23.
23. Tsiatis A.C., Norris-Kirby A., Rich R.G., et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn 2010, 12:425-432.
24. Weichert W., Schewe C., Lehmann A., et al. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn 2010, 12:35-42.
25. Whitehall V., Tran K., Umapathy A., et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn 2009, 11:543-552.
26. Ogino S., Kawasaki T., Brahmandam M., et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 2005, 7:413-421.
27. Simi L., Pratesi N., Vignoli M., et al. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 2008, 130:247-253.
28. Hurst C.D., Zuiverloon T.C., Hafner C., et al. A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. BMC Res Notes 2009, 2:66.